Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Journal of Urology

Volumn 191, Issue 4, 2014, Pages 1045-1050

  Roehrborn, Claus G ^a   Chapple, Christopher ^b   Oelke, Matthias ^c   Cox, David ^d   Esler, Anne ^e   Viktrup, Lars ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d ELI LILLY AND COMPANY   (United States)

^e SYNEOS HEALTH   (United States)

Author keywords

drug evaluation; lower urinary tract symptoms; prostate; prostatic hyperplasia; tadalafil

Indexed keywords

PLACEBO; TADALAFIL; TAMSULOSIN;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; MIDDLE AGED; MULTICENTER STUDY; POST HOC ANALYSIS; POSTVOID RESIDUAL URINE VOLUME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; URINE FLOW RATE; UROFLOWMETRY; BODY MASS; DRUG EFFECT; MAXIMUM URINARY FLOW RATE; MEDIAN URINARY FLOW RATE; RECOMMENDED DRUG DOSE;

DRUG EVALUATION; LOWER URINARY TRACT SYMPTOMS; PROSTATE; PROSTATIC HYPERPLASIA; TADALAFIL;

CARBOLINES; DRUG ADMINISTRATION SCHEDULE; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; URINATION;

EID: 84898434005     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.10.074     Document Type: Article

References (18)

1. Roehrborn CG: Pathology of benign prostatic hyperplasia. Int J Impot Res, suppl., 2008; 20: S11.
2. M. Oelke, A. Bachmann, and A. Descazeaud et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction Eur Urol 64 2013 118
3. H. Hashim, M. Elhilali, and T.E. Bjerklund Johansen et al. The immediate and 6-mo reproducibility of pressure-flow studies in men with benign prostatic enlargement Eur Urol 52 2007 1186
4. M. Belal, and P. Abrams Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 2: noninvasive urodynamics and combination of measures J Urol 176 2006 29
5. M. Oelke, K. Hofner, and U. Jonas et al. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume Eur Urol 52 2007 827
6. K.T. McVary, C.G. Roehrborn, and A.L. Avins et al. Update on AUA guideline on the management of benign prostatic hyperplasia J Urol 185 2011 1793
7. P. Narayan, and A. Tewari Overview of alpha-blocker therapy for benign prostatic hyperplasia Urology 51 1998 38
8. K.T. McVary, C.G. Roehrborn, and J.C. Kaminetsky et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 177 2007 1401
9. C.G. Roehrborn, K.T. McVary, and A. Elion-Mboussa et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study J Urol 180 2008 1228
10. H. Porst, E.D. Kim, and A.R. Casabe et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial Eur Urol 60 2011 1105
11. R.B. Egerdie, S. Auerbach, and C.G. Roehrborn et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study J Sex Med 9 2012 271
12. M. Oelke, F. Giuliano, and V. Mirone et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial Eur Urol 61 2012 917
13. M.J. Barry, F.J. Fowler Jr., and M.P. O'Leary et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association J Urol 148 1992 1549
14. W. Schäfer, P. Abrams, and L. Liao et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies Neurourol Urodyn 21 2002 261
15. F. Giuliano, S. Uckert, and M. Maggi et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia Eur Urol 63 2013 506
16. R. Dmochowski, C. Roehrborn, and S. Klise et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial J Urol 183 2010 1092
17. G.W. Drach, T.N. Layton, and W.J. Binard Male peak urinary flow rate: relationships to volume voided and age J Urol 122 1979 210
18. K. Kawabe, M. Yoshida, and Y. Homma Silodosin, a new alpha1A- adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men BJU Int 98 2006 1019